

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problems Mailbox.**

**THIS PAGE BLANK (USPTO)**



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>5</sup> : <b>A61K 49/00</b>		<b>A1</b>	(11) International Publication Number: <b>WO 94/21301</b>
			(43) International Publication Date: 29 September 1994 (29.09.94)
(21) International Application Number: <b>PCT/GB94/00521</b>		(74) Agents: MARS DEN, John, Christopher et al.; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).	
(22) International Filing Date: 16 March 1994 (16.03.94)			
(30) Priority Data: 9305349.4 16 March 1993 (16.03.93) GB		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for GB only): HOLMES, Michael, John [GB/GB]; Frank B. Dehn & Co., Imperial House, 15-19 Kingsway, London WC2B 6UZ (GB).		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicant (for all designated States except US): NYCOMED IMAGING A.S [NO/NO]; Nycoveien 2, P.O. Box 4220 Torshov, N-0401 Oslo 4 (NO).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BERG, Arne [NO/NO]; Stasjonsveien 37 D, N-1300 Sandvika (NO). DUGSTAD, Harald [NO/NO]; Jupiterveien 13, N-0489 Oslo (NO). FOSS, Per, Antonius [NO/NO]; Konventveien 3 B, N-0377 Oslo (NO). KLA VENESS, Jo [NO/NO]; Midtåsen 5, N-1166 Oslo (NO). ØSTENSEN, Jonny [NO/NO]; Lønneveien 8 C, N-1053 Oslo (NO). RONGVED, Pål [NO/NO]; Hovdens vei 11, N-1450 Nesoddtangen (NO). STRANDE, Per [NO/NO]; Nordengveien 78 A, N-0755 Oslo (NO).			
(54) Title: IMPROVEMENTS IN OR RELATING TO CONTRAST AGENTS			
(57) Abstract			
<p>Oil-in-water emulsions in which the oil phase comprises condensed or dissolved oil-soluble gas/fluid or gas precursor are useful as ultrasound contrast agents. Such products contain insignificant amounts of free gas bubbles or microbubbles in their stored form and exhibit good storage stability, but may be designed to promote rapid microbubble generation immediately before or upon administration.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

- 1 -

"Improvements in or relating to contrast agents"

5           This invention relates to novel contrast agents, more particularly to new contrast agents of use in diagnostic ultrasound imaging.

          Ultrasound imaging is based on penetration of ultrasound waves, e.g. in the frequency range 1-10 MHz, into a human or animal subject via a transducer, the ultrasound waves interacting with interfaces of body tissues and fluids. Contrast in an ultrasound image derives from differential reflection/absorption of the sound waves at such interfaces; results may be enhanced by the use of Doppler techniques, including the use of colour Doppler to evaluate blood flow.

          It has long been realised that it may be advantageous to increase the difference in acoustic properties of different tissues/fluids using contrast agents, and since the use of indocyanine green in 1968 as the first ultrasound contrast agent many other potential agents have been examined. These include emulsions, solid particles, water-soluble compounds, free gas bubbles and various types of encapsulated gas-containing systems. It is generally accepted that low density contrast agents which are easily compressible are particularly efficient in terms of the acoustic backscatter they generate; gas-containing and gas-generating systems thus tend to exhibit markedly greater efficacy than other types of contrast agent.

          Three ultrasound contrast agents are now commercially available or in late clinical development, these being Echovist®, based on gas-containing galactose microcrystals; Levovist®, comprising gas-containing galactose microcrystals coated with fatty acid; and Albunex®, which comprises gas bubbles encapsulated by partially denatured human serum albumin. Clinical use

- 2 -

of these agents is restricted, however, by their short contrast half-lives (i.e. by their relative lack of stability in vivo) and their limited shelf life.

Accordingly there is a continuing need for ultrasound contrast agents, especially for cardiac and non-cardiac perfusion studies, which combine good storage stability with stability in vivo, preferably for at least several passages of circulation in the case of intracardiac injections.

10 A further disadvantage of microparticulate ultrasound contrast agents such as Echovist® and Levovist® is that they need to be formulated prior to administration, e.g. by addition of an appropriate carrier liquid and agitation by shaking. This  
15 inevitably causes some delay and there is thus a need for improved ultrasound contrast agents which can be stored for substantial periods of time (e.g. at least 12 months, preferably 2-3 years) in "ready to use" form.

The present invention is based on our findings that  
20 this objective may be fulfilled by oil-in-water emulsion-based contrast agents containing oil-soluble gases/fluids or gas precursors in condensed or dissolved form in the dispersed oil phase.

Thus according to one feature of the invention  
25 there is provided an ultrasound agent consisting of a biocompatible oil-in-water emulsion wherein the oil phase comprises an oil-soluble gas/fluid or gas precursor.

A characteristic feature of the contrast agents of  
30 the invention is that they are substantially completely free from gas bubbles/microbubbles in their stored form prior to administration; rapid microbubble generation may ensue following administration, however, e.g. by intravenous or intra-arterial injection, or may be  
35 induced immediately before such administration, e.g. as described in greater detail hereinafter. In this respect the products of the invention may be contrasted

- 3 -

with existing ultrasound contrast agents, which in general contain free gas in their stored form, e.g. as inclusions in the voids of their crystal structures and/or adhered to their surfaces in the case of micro-particulate materials such as Echovist® and Levovist® or in encapsulated form in materials such as Albunex®.

Gases of use in the contrast agents of the invention preferably have low water solubility to ensure their preferential solubility in the lipophilic oil phase of the emulsion and to enhance the stability of the microbubbles generated in the aqueous environment of the bloodstream following intravenous or intra-arterial injection of the contrast agents. It will be appreciated, however, that the solubility of the gas in the oil phase should preferably not be so high as to inhibit such microbubble generation following administration, although microbubble formation may if desired be enhanced in such situations by, for example, preheating the emulsion prior to administration, e.g. as described in greater detail hereinafter. Appropriate gases thus include, for example, inert gases such as helium, neon, argon, krypton or xenon; hydrocarbons such as methane, acetylene or 3-methylbut-1-ene; halogenated hydrocarbons, including haloalkanes such as methyl bromide, C<sub>1-4</sub> hydrofluoroalkanes such as hexafluoropropane, and, more preferably, perfluoroalkanes such as perfluoromethane or perfluorobutane and sulphur halides such as sulphur hexafluoride etc.

The term "gas" as used herein includes any substance in the gaseous form at the normal human body temperature of 37°C, and thus embraces a variety of oil-soluble substances which are liquid at ambient temperatures, e.g. 20-25°C. Examples of suitable substances, which may be regarded as being intermixed with the oil phase of the emulsion in the context of being dissolved therein, include optionally halogenated

- 4 -

and/or otherwise substituted hydrocarbons, aliphatic and cyclic ethers, silanes, arsines and sulphur halides, for example such as the following:

5	<u>Substance</u>	<u>boiling point (°C)</u>
	4-methyl-1,3-dioxolan-2-one	24.2
	dibromodifluoromethane	24.5
	1-nitroheptafluoropentane	25.0
10	tetramethylsilane	26.5
	but-2-yne	27.0
	2-methylbutane	27.8
	disulphur decafluoride	29.0
	perfluoropent-1-ene	29-30
15	pent-1-ene	30.0
	1,2-difluoroethane	30.7
	2-methylbut-1-ene	31.2
	furan	31.4
	n-butyl fluoride	32.5
20	methyl isopropyl ether	32.5
	tris-trifluoromethylarsine	33.3
	2-methylbuta-1,3-diene	34.1
	propylene oxide	34.2
	diethyl ether	34.5
25	isopropyl chloride	35-36
	pentane	36.1
	pent-2-ene (trans, cis)	36.3-36.9

The term "fluid" as used herein denotes a volatile  
 30 organic substance, preferably having a boiling point not  
 exceeding 60°C. It will be appreciated that the above-  
 described requirements of low water solubility and  
 preferential (but desirably not excessive) oil  
 solubility as applied to such fluids should be  
 35 interpreted as ones of miscibility and that the  
 requirement of dissolution in the oil phase of the  
 emulsion should be interpreted as one of being

- 5 -

intermixed therewith.

Examples of fluids include 1,1-dichloroethylene, 2-methylbut-2-ene, 3,3-dimethylbut-1-yne, dimethylaminoacetone, perfluoropentane, cyclopentane, cyclopentene and 2,3-pentadiene. It will be appreciated that such fluids having boiling points in excess of 37°C will in general not generate gas microbubbles following administration. They will, however, generate fluid microbubbles which by virtue of the relatively low density of the fluid will provide an ultrasound contrast effect.

Examples of oil-soluble gas precursors include organic carbonates, e.g. compounds of formula

RO.CO.OM

where R is a lipophilic organic group and M is a physiologically acceptable cation. Such substances will generate carbon dioxide at pHs of about 7 or less, e.g. under the conditions prevailing in the bloodstream following intravenous or intra-arterial administration. Where such precursors relying on pH activation are employed it may be advantageous to incorporate an ionophore, e.g. nigericin, into the emulsion to facilitate proton transfer through the oil phase.

Other gas precursors include nitrogen-generating substances such as pyrazolines, pyrazoles, triazolines, diazoketones, diazonium salts, tetrazoles, azides and azide/carbonate mixtures, which may, for example, be activated by irradiation, e.g. by UV light, for example immediately prior to administration. Substances which generate carbon dioxide upon photolysis, e.g. certain cyclic ketones, lactones and carbonates, may similarly be useful.

Oxygen-generating gas precursors include peracids such as perbenzoic acid.

Thermally degradable gas precursors, which are

- 6 -

activated by body heat following administration, may also be used, an example of such a substance being a thermally degradable carboxylic acid such as 2-methylactic acid.

5           A further class of gas precursors comprises substances which are enzymically degraded in vivo with accompanying generation of gas. Examples include methylene diesters (e.g. prepared using techniques such as are described in WO-A-9317718 and WO-A-9318070, the  
10           contents of which are incorporated herein by reference), which are cleaved by common esterases leading to evolution of carbon dioxide. Another useful substance is hydrogen peroxide, which is soluble in lipophilic media such as ethers and which is enzymatically degraded  
15           in vivo with evolution of oxygen. If hydrogen peroxide is used it may be advantageous also to incorporate an antioxidant stabiliser.

          The oil phase of the emulsion may consist essentially of gas/fluid, together with any necessary  
20           biocompatible emulsification agents, in circumstances where the gas or fluid is itself capable of forming a stable emulsion; in such cases a critical requirement is that the gas or fluid is present in condensed rather than gaseous form, e.g. through application of pressure  
25           where necessary.

          More commonly, the oil phase will consist essentially of gas/fluid or gas precursor dissolved in at least one lipophilic solvent component, together with any necessary biocompatible emulsification agents,  
30           including surfactants and other stabilisers. It will be appreciated that such emulsification agents may be preferentially dissolved or dispersed in either the oil phase or the aqueous phase as needed for specific emulsion systems.

35           One useful class of lipophilic solvent components for the oil phase of emulsions according to the invention comprises highly fluorinated organic compounds

- 7 -

such as have been proposed as components of "artificial bloods" - see for example EP-A-0231091 and WO-A-8910118, the contents of which are incorporated herein by reference. It should be noted that when used in

5 artificial bloods these fluorinated compounds are believed to effect oxygen transport by complexing with oxygen molecules, in contrast to the present invention where they effectively provide a solvent medium for the lipid-soluble gas/fluid.

10 Highly fluorinated organic compounds which may be used in accordance with the invention include aliphatic and cycloaliphatic perfluorocarbons, e.g. containing up to 20 carbon atoms, such as perfluoro-2,2,4,4-tetramethylpentane, perfluorooctane, perfluorodecane,

15 perfluorotrimethylcyclohexane, perfluoroisopropylcyclohexane, perfluorodecalin, perfluoroindane, perfluorotrimethylbicyclo[3.3.1]nonane, perfluorobicyclo[5.3.0]decane, perfluoromethyladamantane and perfluorodimethyladamantane; bromo-substituted

20 analogues of the foregoing, such as perfluorooctyl bromide; aliphatic and cycloaliphatic perfluoroamines, e.g. containing up to 20 carbon atoms, such as perfluorotripropylamine, perfluorotributylamine, perfluoro-N-methyldecahydroquinoline, perfluoro-4-

25 methyloctahydroquinolizidine and perfluoro-1-azatricyclic amines; perfluoro ethers and mixtures of any of the foregoing. Preferred compounds of this type include perfluorooctyl bromide and perfluorodecalin, which latter may for example be used in combination with

30 perfluorotripropylamine, e.g. as in the product Fluosol DA®.

Surfactants may be used as emulsification agents to stabilise the emulsion or themselves to provide the lipophilic solvent component in which the gas/fluid or

35 gas precursor is dissolved. Appropriate biocompatible surfactants which may be useful thus include anionic surfactants, for example alkali metal salts of fatty

- 8 -

acids such as sodium dodecanoate, alkali metal alkyl sulphates such as sodium lauryl sulphate and alkali metal sulphonated esters such as sodium dioctyl sulphosuccinate (docusate) and, more preferably, 5 nonionic or zwitterionic surfactants. Examples of these latter categories include fatty alcohols such as n-decanol, polyoxyethylene-polyoxypropylene copolymers (e.g. poloxamers such as Pluronic® F68), sorbitan fatty acid esters such as Span-type materials and 10 polyoxyethylated analogues thereof such as Tween-type materials, phospholipids (e.g. phosphatidyl choline (i.e. lecithin) or dioleoylphosphatidyl diethanolamine), and polyethylene glycol esters of fatty acids (e.g. Cremaphor® products).

15 Polymerisable amphiphiles, for example such as those described in WO-A-9217212 (the contents of which are incorporated herein by reference), may also be used as surfactants; polymerisation of such amphiphiles, e.g. by UV-irradiation or other appropriate form of 20 initiation, may if desired be effected after emulsification.

Appropriate surfactants may be employed in the form of multicompartment vesicles, e.g. as described by Kim et al. in Biochim. Biophys. Acta 728 (1983) p. 339 and 25 in EP-A-0280503. These may be regarded as consisting of lipid bilayer membranes enclosing a plurality of non-concentric cores, i.e. having a quasi-honeycomb structure. A plurality of amphipathic lipids may conveniently be used, at least one of these 30 advantageously having a net negative charge; one or more neutral lipids may also be present. Representative components thus include phosphatidyl serines, phosphatidylglycerols such as dimyristoyl phosphatidylglycerol, phosphatidic acids such as dimyristoyl 35 phosphatidic acid, phosphatidyl cholines such as dioleoylphosphatidyl choline or dipalmitoylphosphatidyl choline, phosphatidyl ethanolamines, dioleoyl lecithin,

- 9 -

cholesterol, triolein, trioctanoin and other oils/triglycerides and derivatives thereof.

Other lipophilic substances which may be used in the emulsions, e.g. as stabilising components, include  
5 antioxidants such as tocopherols or thiocctic acid, perfluorinated surfactants which both dissolve and stabilise the lipid-soluble gas or gas precursor, liquid crystals, compounds for making Langmuir-Blodget films, and lipophilic biodegradable polymers, for example block  
10 copolymers, (e.g. as described in WO-A-9204392 or WO-A-9317718). Oil-soluble carrier molecules for the gas/fluid may also be employed; porphyrins may be suitable carriers for this purpose.

Additives such as surfactant assistants may also be  
15 employed, for example viscosity enhancers such as sugars, e.g. sucrose.

One particularly useful class of emulsions comprises fat-based emulsions such as the commercially available intravenously administrable emulsions Liposyn®  
20 (Abbot Laboratories), Intralipid® (Kabi Vitrum) and Soyacal® (Alpha Therapeutic). Such emulsions are typically based on soyabean oil, egg yolk phospholipid, glycerin and water for injection, and typically have emulsion particles less than 0.5  $\mu\text{m}$  in diameter, similar  
25 in size to naturally occurring chylomicrons. Advantages of their use may include long shelf life, improved vascular contrast half-life and sustained release of gas.

If desired, the oil phase of contrast agents  
30 according to the invention may additionally contain suspended solid microparticles of one or more biotolerable minerals, e.g. having a particle size of less than 1 micron, preferably less than 0.2 microns. Such microparticles, which may for example comprise  
35 silica or iron oxide, may act as nucleation sites, promoting generation of gas at the solid/liquid interface following administration of the contrast agents.

- 10 -

The precise constitution of contrast agents according to the invention may be varied widely depending on such factors as the particular components used, the specific usage envisaged and the intended  
5 microbubble size following administration.

Thus, for example, the size of microbubbles formed following administration will generally increase as the concentration of gas/fluid is increased, also being affected by the nature of the materials forming the oil  
10 phase. Where the contrast agent contains a dissolved gas this may in general be at any desired level up to saturation or even supersaturation, e.g. with the contrast agent being stored under pressure.

In the case of pressurised contrast agents  
15 microbubble formation may commence before administration of the agent, e.g. as soon as the vial or other form of container is broached, and will continue in vivo following administration. Non-pressurised contrast agents will generate microbubbles in vivo as a result  
20 of, for example, warming of the contrast agent to body temperature, diffusion of blood components into the stabilising material and/or gradual breakdown of the emulsion. Alternatively, microbubble generation may be induced prior to administration, for example by  
25 preheating the emulsion, e.g. by microwave heating.

As noted above, preferred oil-soluble gases are those having low solubility in water. This encourages the gas to associate with lipophilic components of the emulsion, thereby further enhancing the stability of the  
30 microbubbles, and may also lead to generation of a flexible microbubble/lipophile matrix, e.g. in the form of coated microbubbles. It is recognised in the art that such flexible structures are particularly advantageous by virtue of their enhanced ultrasound  
35 contrast effect when compared to more rigid encapsulated microbubble systems.

- 11 -

Contrast agents according to the invention may be prepared by any convenient method. Thus, for example, a gas/fluid-containing or gas precursor-containing oil phase, e.g. consisting of a condensed oil-soluble gas/fluid or a solution of an oil-soluble gas/fluid or gas precursor in at least one lipophilic solvent medium, may be emulsified in an aqueous phase so as to form an oil-in-water emulsion, e.g. using conventional techniques such as homogenisation or sonication, or the desired gas/fluid or gas precursor may be incorporated into the oil phase of a preformed oil-in-water emulsion.

Where an oil-soluble gas is employed this may, for example, be dissolved in a chosen lipophilic solvent medium, e.g. at elevated pressure, the resulting oil thereinafter being emulsified, advantageously under a pressure of excess gas and, if necessary or desired, in the presence of one or more biocompatible emulsifiers. Analogous techniques may be used when an oil-soluble fluid or gas precursor is employed. Alternatively, gas may be incorporated into a preformed emulsion, for example by passing gas through the emulsion and/or by maintaining the emulsion under an elevated pressure of gas.

The ultrasound contrast agents of the invention may, for example, be administered enterally or parenterally, although there may be advantages in particular applications in administration directly into body cavities such as the Fallopian tubes. In general, however, intravascular administration, most commonly by intravenous injection, is most likely to be employed, in order to enhance vascular imaging, including cardiac and extracardiac perfusion.

It will be appreciated that contrast agents for intravenous administration should generate microbubbles small enough to pass through the capillary bed of the pulmonary system. The agents should therefore preferably be such as to generate microbubbles having

- 12 -

diameters of less than 10  $\mu\text{m}$ , preferably in the range 0.2-8  $\mu\text{m}$ , e.g. 0.3-7  $\mu\text{m}$ .

The following non-limitative examples serve to illustrate the invention.

5

#### EXAMPLE 1

Span 20 (0.1021 g) was dissolved in n-pentane (10ml). Tween 60 (0.5466 g) dissolved in water (40 ml) was added, and the mixture was emulsified at 0°C using an Ystral homogenizer, yielding a fine, stable emulsion. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 5 ml distilled water at 37°C, which is above the boiling point of n-pentane. The obtained ultrasound attenuation was stable for 20 minutes.

#### EXAMPLE 2

Span 20 (0.1193 g) was dissolved in tetramethylsilane (TMS) (10 ml). Tween 60 (0.9535 g) dissolved in water (40 ml) was added, and the mixture was emulsified at 0°C using an Ystral homogenizer, yielding a fine, stable emulsion. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 5 ml distilled water at 37°C, which is above the boiling point of TMS. A strong ultrasound attenuation was obtained, and the signal was stable for 20 minutes.

#### EXAMPLE 3

30

The emulsion from Example 2 above (0.35 ml) was injected into distilled water (6.65 ml) at 37°C, which is above the boiling point of TMS. An echogenic effect which showed a maximum after 4 minutes was obtained, and the signal was stable for 20 minutes.

- 13 -

EXAMPLE 4

The emulsion from Example 2 above (2 ml) was injected into distilled water (5 ml) at 0°C, and the diluted  
5 emulsion slowly heated to 37°C. During the heating process, the ultrasound attenuation was measured and the contrast effect was found to increase slowly over a period of 20 minutes, revealing gas release with time.

10 EXAMPLE 5

Span 20 (0.0987 g) was added to furan (10 ml). Tween 60 (1.0098 g) dissolved in water (40 ml) was added, and emulsified at 0°C using an Ystral homogenizer, yielding  
15 a fine, stable emulsion. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 5 ml distilled water at 37°C, which is above the boiling point of furan. An echogenic effect was obtained, and the signal was stable for 20 minutes.

20

EXAMPLE 6

Pentane (5 ml) was added to didodecyldimethylammonium bromide (0.68 g) dissolved in water (40 ml) and the  
25 mixture was emulsified at 0°C using an Ystral homogenizer, yielding a fine emulsion stabilized by a lamellar liquid crystalline phase. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 5 ml distilled water at 37°C. An  
30 echogenic effect was obtained, and the signal was stable for 20 minutes.

EXAMPLE 7

35 Pentane (5 ml) was added to sodium dodecyl sulphate (0.56 g) and 1-decanol (0.60 g) dissolved in water (40 ml) and the mixture was emulsified at 0°C using an Ystral homogenizer, yielding a fine emulsion stabilized

- 14 -

by a lamellar liquid crystalline phase. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 5 ml distilled water at 37°C. An echogenic effect was obtained, and the signal was stable for 20 minutes.

#### EXAMPLE 8

Span 20 (0.10 g) was dispersed in perfluorodecalin (4 ml) which then was saturated with sulphur hexafluoride at 4°C. Tween 60 (0.45 g) was dissolved in water (36 ml), cooled to 4°C and the two solutions were emulsified at 4°C using an Ystral homogenizer at 20 000 rpm for 30 seconds. Ultrasound attenuation was measured by injecting 2 ml of the emulsion into 6 ml of distilled water at 4°C and heating slowly to 37°C. An attenuation of 2 dB/cm or higher was observed for approximately 120 seconds.

#### EXAMPLE 9

n-Decanol (0.5 ml) and sodium dodecanoate (0.50 g) were dispersed in water (36 ml). Perfluorodecalin (4 ml) was cooled to 4°C and saturated with sulphur hexafluoride. The two solutions were emulsified at 4°C using an Ystral homogenizer at 20 000 rpm for 30 seconds. Ultrasound attenuation was measured by mixing 2 ml of the emulsion with 6 ml of distilled water at 37°C. A strong attenuation (> 2 dB/cm) was observed for approximately 30 seconds.

#### EXAMPLE 10

The emulsion from Example 9 (2 ml) was mixed with distilled water (6 ml) at 4°C and the diluted emulsion was slowly heated to 37°C. The ultrasound attenuation was measured and a maximum attenuation of 2.7 dB/cm was observed after approximately 30 seconds.

- 15 -

EXAMPLE 11

n-Decanol (0.5 ml) and sodium dodecanoate (0.50 g) were dispersed in water (36 ml). Perfluorodecalin (4 ml) was cooled to 4°C and saturated with xenon. The two solutions were emulsified at 4°C using an Ystral homogenizer at 20 000 rpm for 30 seconds. Ultrasound attenuation was measured by mixing 2 ml of the emulsion with 6 ml of distilled water at 37°C. The ultrasound attenuation increased from 1 to approximately 3 dB/cm over 5 minutes.

EXAMPLE 12

n-Decanol (0.5 ml) and sodium dodecanoate (0.50 g) are dispersed in water (36 ml). Perfluorooctyl bromide (4 ml) is cooled to 4°C and saturated with xenon. The two solutions are emulsified at 4°C using an Ystral homogenizer at 20 000 rpm for 30 seconds. Ultrasound attenuation is measured by mixing 2 ml of the emulsion with 6 ml of distilled water at 37°C.

EXAMPLE 13

Intralipid® (Kabi Vitrum, Stockholm, Sweden), Fluosol® (Alpha Therapeutic Ltd, UK) or perfluorooctyl bromide (10 ml) is cooled to 4°C in an autoclave. The emulsions are stirred while being pressurised with xenon (20 atm) for 16 hours. The stirring is then stopped and the pressure slowly released. Ultrasound attenuation is measured by mixing 2 ml of each emulsion with 6 ml of distilled water at 37°C.

EXAMPLE 14

Perfluoro-n-butane (1.6g) at a pressure of 2.5 atmospheres was added to perfluorodecalin (0.4 g) cooled to -5°C, this being below the boiling point of

- 16 -

perfluoro-n-butane (ca. -2°C). The resulting oil was emulsified with 40 ml of an aqueous solution containing Pluronic F68 (1% w/w) and sucrose (30% w/w) by sonication for 20 minutes in a cooled closed plastic vessel. Droplet diameter for the thus-obtained oil-in-water emulsion was observed microscopically to be about 1 micron; no significant change was evident after storage for one week. A portion (5 ml) of the emulsion in a 15 ml vessel was heated to 80°C in an 800 W microwave oven (typical heating time 8-10 seconds), cooled and filtered (Millipore, 10  $\mu$ m). Microscopy confirmed the formation of perfluoro-n-butane microbubbles having stabilising coatings of perfluorodecalin. The in vitro acoustic attenuation for such a microbubble dispersion diluted to have a total oil content of 0.2% w/w was greater than 10 dB/cm over the frequency range 1-6 MHz and was stable for more than 10 minutes. A similar sample prepared without preheating the emulsion and tested at 37°C exhibited an in vitro acoustic attenuation which increased from 2 dB/cm to 6 dB/cm over 7 minutes as microbubbles were generated spontaneously.

- 17 -

CLAIMS

1. An ultrasound agent consisting of a biocompatible oil-in-water emulsion wherein the oil phase comprises an oil-soluble gas/fluid or gas precursor.
2. A contrast agent as claimed in claim 1 wherein the gas/fluid is an inert gas, an optionally halogenated or otherwise substituted hydrocarbon, an aliphatic or cyclic ether, a silane, an arsine or a sulphur halide.
3. A contrast agent as claimed in claim 2 wherein the gas/fluid is a perfluoroalkane.
4. A contrast agent as claimed in claim 2 wherein the gas/fluid is selected from xenon, n-pentane, furan, tetramethylsilane, sulphur hexafluoride and perfluoro-n-butane.
5. A contrast agent as claimed in claim 1 wherein the gas precursor is an organic carbonate; a pyrazoline, pyrazole, triazoline, diazoketone, diazonium salt, tetrazole, azide or azide/carbonate mixture; a photolysable cyclic ketone, lactone or carbonate; a peracid; a thermally degradable carboxylic acid; an enzymically degradable methylene diester or hydrogen peroxide.
6. A contrast agent as claimed in any of claims 1 to 4 wherein the oil phase of the emulsion consists essentially of condensed gas/fluid together with any necessary biocompatible emulsification agents.
7. A contrast agent as claimed in any of claims 1 to 5 wherein the oil phase of the emulsion consists essentially of gas/fluid or gas precursor dissolved in at least one lipophilic solvent component together with any necessary biocompatible emulsification agents.

- 18 -

8. A contrast agent as claimed in claim 7 wherein the lipophilic solvent component is selected from aliphatic and cycloaliphatic perfluorocarbons and bromo-substituted analogues thereof, aliphatic and  
5 cycloaliphatic perfluoroamines, perfluoro ethers and mixtures of any of the foregoing.

9. A contrast agent as claimed in claim 8 wherein the lipophilic solvent component is perfluorooctyl bromide,  
10 perfluorodecalin or a mixture of perfluorodecalin and perfluorotripropylamine.

10. A contrast agent as claimed in any of claims 6 to 9 containing as emulsification agent one or more  
15 surfactants selected from alkali metal salts of fatty acids, alkali metal alkyl sulphates and sulphonated esters, polyoxyethylene-polyoxypropylene copolymers, sorbitan fatty acid esters and polyoxyethylated analogues thereof, phospholipids, polyethylene glycol  
20 esters of fatty acids, polymerisable amphiphiles and multicompartment vesicle surfactant systems.

11. A contrast agent as claimed in any of claims 7 to 10 wherein the emulsification agent also acts as the  
25 lipophilic solvent component.

12. A contrast agent as claimed in any of claims 1 to 5 wherein the oil phase of the emulsion comprises soyabean oil and egg yolk phospholipid and the aqueous phase  
30 comprises glycerin and water for injection.

13. A contrast agent as claimed in any of the preceding claims wherein microparticles of one or more biotolerable minerals are suspended in the oil phase.

35

14. A process for the preparation of an ultrasound contrast agent as defined in claim 1 which comprises either (i) emulsifying an oil phase comprising either a

- 19 -

condensed oil-soluble gas/fluid or a solution of an oil-soluble gas/fluid or gas precursor in at least one lipophilic solvent component in an aqueous phase so as to form an oil-in-water emulsion or (ii) incorporating a  
5 desired oil-soluble gas/fluid or gas precursor into the oil phase of a preformed oil-in-water emulsion.

15. A method of generating enhanced images of a human or non-human animal body which comprises administering  
10 to said body a contrast agent as claimed in any of claims 1 to 13 and generating an ultrasound image of at least a part of said body.

## INTERNATIONAL SEARCH REPORT

Int. l. onal. l. onation No.

PCT/GB 94/00521

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 5 A61K49/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 5 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP,A,0 245 019 (MICHAEL DAVIS) 11 November 1987 see claims ---	1-15
X	US,A,4 684 479 (JOSEPH S. D' ARRIGO) 4 August 1987  see column 1, line 26 - line 31 see column 2, line 22 - line 37 see column 6, line 45 - line 55	1,6,7, 10,11, 14,15
Y	---	1-15
X,P	WO,A,93 05819 (STEVEN QUAY) 1 April 1993  see examples; tables II,IV ---	1-4, 6-11,14, 15
	--- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*I\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*&\* document member of the same patent family

Date of the actual completion of the international search

27 July 1994

Date of mailing of the international search report

16. 08. 94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Berte, M

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 94/00521

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	EP,A,0 554 213 (SINETICA SA) 4 August 1993  see claims; tables ---	1-4, 6-12, 14, 15
Y	US,A,4 900 540 (PATRICK J. RYAN) 13 February 1990 see claims -----	1-15

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB94/00521

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claim 15 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 94/00521

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0245019	11-11-87	JP-A- 62289531	16-12-87
US-A-4684479	04-08-87	NONE	
WO-A-9305819	01-04-93	AU-A- 2550392	27-04-93
		CN-A- 1073104	16-06-93
		EP-A- 0605477	13-07-94
		PT-A- 100867	29-10-93
EP-A-0554213	04-08-93	AU-A- 3186093	29-07-93
		CA-A- 2085525	25-07-93
		CN-A- 1074619	28-07-93
US-A-4900540	13-02-90	NONE	

**THIS PAGE BLANK (USPTO)**